MHRA adds 'more prominent warning' to montelukast to boost awareness of side effects

7 May 2024

Getty/katleho Seisa

By Emma Wilkinson

The medicines regulator has warned healthcare professionals to be alert to the risk of neuropsychiatric reactions in patients taking asthma drug montelukast.

It comes as the Medicines and Healthcare products Regulatory Agency (MHRA) also announced it would be adding more prominent boxed warnings, formerly known as Black Box warnings, to the medicine







Log in or join to read more

You might also like